Ancient herb meets modern medicine: ashwagandha trial for ovarian cancer

NCT ID NCT05610735

First seen Mar 30, 2026 · Last updated May 15, 2026 · Updated 7 times

Summary

This study tests whether adding Ashwagandha (an herbal supplement) to standard chemotherapy (DOXIL) is safe and effective for people with ovarian cancer that has returned after initial treatment. About 72 participants will first help find the best Ashwagandha dose, then researchers will measure how well the combination controls tumor growth. The goal is to improve outcomes without increasing side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UofL Health Brown Cancer Center

    RECRUITING

    Louisville, Kentucky, 40202, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.